Project Grant K99HL179259
Award Date 5/4/26
Completion Date 4/30/28
Dollars Obligated $140K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant of $117,525 on July 7, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate cellular adaptation mechanisms in response to one-carbon metabolism perturbation. The research focuses on understanding how erythroid cells respond to folate deficiency through a combination of genome-wide CRISPR screening, RNA sequencing, and molecular...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $865,286 to Boston Children's Hospital (The Children's Hospital Corporation) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with a completion date of June 30, 2029. This research initiative will produce a high-resolution spatiotemporal lineage map of cardiac development by integrating advanced lineage tracing, spatial, and single-cell...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a $445,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for a three-year period from July 15, 2025, through June 30, 2028. This award supports research determining genetic mechanisms that drive in vitro hematopoiesis, specifically investigating how the tropomyosin 1 (TPM1) gene impacts the development of...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Leland Stanford Junior University a project grant of $215,931 on June 23, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research investigating the role of COUP-TFII in human vein development through January 12, 2028. The research leverages a newly established stem cell differentiation protocol that generates highly pure venous endothelial cells (>85%...
- Federal Grant Award Summary Boston Children's Hospital received a $267,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, with completion anticipated by July 31, 2027. The award funds research to identify shared molecular mechanisms underlying congenital heart disease (CHD) and neurodevelopmental delay and disability (NDD) by characterizing dysregulated gene expression in...
- Federal Project Grant Award Summary Boston Children's Hospital received an $833,594 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of May 31, 2029. The grant funds basic research investigating the pro-regenerative potential of PONTIN (an AAA+ ATPase protein) in cardiac tissue, with the objective of identifying druggable pathways to stimulate heart...
- Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant totaling $144,817 under the Cardiovascular Diseases Research program (CFDA 93.837) for the period May 8, 2026 through April 30, 2028. This research initiative, titled "Endocardial S1PR1 Internalization Drives Congenital Heart Disease via Notch Signaling Dysregulation," will produce fundamental scientific knowledge regarding the molecular mechanisms underlying...
- Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital a Project Grant totaling $865,694 (awarded June 5, 2025; completion date April 30, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on neuropilin-2 (NRP2) signaling and lymphatic function. The research focuses on understanding how NRP2, a transmembrane receptor in lymphatic endothelial cells, functions as a dynamic regulator of...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded the University of Southern California a $790,498 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) beginning September 1, 2025, and extending through June 30, 2030. The grant supports basic research investigating the novel role of PCBP1 (poly(C) binding protein 1), an RNA-binding protein, and its splicing target AARS2 in regulating vascular endothelial growth factor (VEGF)...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a $888,836 Project Grant (CFDA 93.837: Cardiovascular Diseases Research) effective August 1, 2025, through May 31, 2029, to develop novel approaches for delivering Factor VIII (FVIII) expression in hemophilia A treatment. The research addresses limitations in current adeno-associated viral (AAV) vector-mediated gene therapy by investigating targeted...